<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>BioScreening.net &#187; New Products</title>
	<atom:link href="http://www.bioscreening.net/category/industry-trends/new-products/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.bioscreening.net</link>
	<description>BioScreening news and events</description>
	<lastBuildDate>Thu, 29 Dec 2011 08:21:20 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3</generator>
		<item>
		<title>Ancient Chinese cures translate into modern Western medicines</title>
		<link>http://www.bioscreening.net/2011/11/28/ancient-chinese-cures-translate-into-modern-western-medicines/</link>
		<comments>http://www.bioscreening.net/2011/11/28/ancient-chinese-cures-translate-into-modern-western-medicines/#comments</comments>
		<pubDate>Mon, 28 Nov 2011 14:45:27 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Asia]]></category>
		<category><![CDATA[Natural Products]]></category>
		<category><![CDATA[New Products]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1357</guid>
		<description><![CDATA[The Chem-TCM is the most comprehensive database of its kind and translates more than 12,000 chemicals from more than 300 Chinese herbs used in traditional Chinese medicine (TCM) into Western terminology. &#8220;Future researchers will now be able to better understand the chemical basis of remedies that have been in use for thousands of years,&#8221; says [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/11/28/ancient-chinese-cures-translate-into-modern-western-medicines/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Vaccine for ovarian, breast cancer shows promise</title>
		<link>http://www.bioscreening.net/2011/11/09/vaccine-for-ovarian-breast-cancer-shows-promise/</link>
		<comments>http://www.bioscreening.net/2011/11/09/vaccine-for-ovarian-breast-cancer-shows-promise/#comments</comments>
		<pubDate>Wed, 09 Nov 2011 18:40:50 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Cell Analysis]]></category>
		<category><![CDATA[Discoveries, Innovations and Patents]]></category>
		<category><![CDATA[Medicinal Chemistry]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[New Products]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[R & D]]></category>
		<category><![CDATA[Reports]]></category>
		<category><![CDATA[USA and Canada]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1312</guid>
		<description><![CDATA[(CBS) A new vaccine that targets ovarian and breast cancer has shown promise in early studies, giving scientists hope they may be closer to stopping the deadly diseases. PICTURES: 25 breast cancer myths busted Known as PANVAC, the vaccine triggers the immune system to attack tumor cells. &#8220;With this vaccine, we can clearly generate immune [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/11/09/vaccine-for-ovarian-breast-cancer-shows-promise/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>XXI Century Database of Traditional Chinese Medicine Released</title>
		<link>http://www.bioscreening.net/2011/10/18/xxi-century-database-of-traditional-chinese-medicine-released/</link>
		<comments>http://www.bioscreening.net/2011/10/18/xxi-century-database-of-traditional-chinese-medicine-released/#comments</comments>
		<pubDate>Tue, 18 Oct 2011 16:18:11 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[New Products]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[R & D]]></category>
		<category><![CDATA[Reports]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1304</guid>
		<description><![CDATA[October 18, 2011 A comprehensive database developed by King’s College London researchers that features the chemical components found in traditional Chinese medicines has been released to market this month, allowing researchers to explore age-old remedies in the search for tomorrow’s new drugs. Provided under licence to Tim Tec LLC, a US-based life science supplier company, [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/10/18/xxi-century-database-of-traditional-chinese-medicine-released/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Body &amp; Mind &#8211; HEALTH U.S. Doctor Cautious About HIV Vaccine</title>
		<link>http://www.bioscreening.net/2011/09/29/body-mind-health-u-s-doctor-cautious-about-hiv-vaccine/</link>
		<comments>http://www.bioscreening.net/2011/09/29/body-mind-health-u-s-doctor-cautious-about-hiv-vaccine/#comments</comments>
		<pubDate>Thu, 29 Sep 2011 19:36:34 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Cell Analysis]]></category>
		<category><![CDATA[Discoveries, Innovations and Patents]]></category>
		<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[HIV Research]]></category>
		<category><![CDATA[Medicinal Chemistry]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[New Products]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[R & D]]></category>
		<category><![CDATA[Reports]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1299</guid>
		<description><![CDATA[A New York City-based infectious disease specialist said a new vaccine developed by Spanish scientists, which could turn HIV into minor infection status, is reason to be cautiously optimistic. Dr. Joseph Rahimian said Thursday news of an HIV vaccine is certainly exciting, but questions remain. “An HIV vaccine has been the holy grail for infectious [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/09/29/body-mind-health-u-s-doctor-cautious-about-hiv-vaccine/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Critical Protein Discovery Could Help Prevent Lethal Ebola Virus</title>
		<link>http://www.bioscreening.net/2011/08/25/critical-protein-discovery-could-help-prevent-lethal-ebola-virus/</link>
		<comments>http://www.bioscreening.net/2011/08/25/critical-protein-discovery-could-help-prevent-lethal-ebola-virus/#comments</comments>
		<pubDate>Thu, 25 Aug 2011 15:25:55 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Cell Analysis]]></category>
		<category><![CDATA[Discoveries, Innovations and Patents]]></category>
		<category><![CDATA[New Products]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[R & D]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1266</guid>
		<description><![CDATA[An international team of scientists has discovered a biochemical route used by the deadly Ebola virus to infect human cells.   Scientists say the discovery points the way to new drugs that could prevent or treat one of the world’s most lethal viral diseases. The Ebola hemorrhagic virus, which got its name from the central African [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/08/25/critical-protein-discovery-could-help-prevent-lethal-ebola-virus/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Sanofi Pasteur to Evaluate Leukocare’s Stabilization Technology for Vaccines</title>
		<link>http://www.bioscreening.net/2011/08/03/sanofi-pasteur-to-evaluate-leukocare%e2%80%99s-stabilization-technology-for-vaccines/</link>
		<comments>http://www.bioscreening.net/2011/08/03/sanofi-pasteur-to-evaluate-leukocare%e2%80%99s-stabilization-technology-for-vaccines/#comments</comments>
		<pubDate>Wed, 03 Aug 2011 18:51:58 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Cell Analysis]]></category>
		<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[Medicinal Chemistry]]></category>
		<category><![CDATA[New Products]]></category>
		<category><![CDATA[R & D]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1232</guid>
		<description><![CDATA[Sanofi Pasteur and Leukocare biotechnology inked a cooperation agreement through which Sanofi’s vaccines division will evaluate Leukocare’s Stabilizing and Protecting Solutions (SPS) platform for improving the shelf-life of certain vaccine formulations. Leukocare’s postcoating technology is designed to both stabilize biotherapeutic and diagnostic products and protect them against the otherwise damaging effects of terminal sterilization by [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/08/03/sanofi-pasteur-to-evaluate-leukocare%e2%80%99s-stabilization-technology-for-vaccines/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Positive agreement received for approval of AXANUM (low-dose ASA/esomeprazole) in Europe</title>
		<link>http://www.bioscreening.net/2011/08/02/positive-agreement-received-for-approval-of-axanum-low-dose-asaesomeprazole-in-europe/</link>
		<comments>http://www.bioscreening.net/2011/08/02/positive-agreement-received-for-approval-of-axanum-low-dose-asaesomeprazole-in-europe/#comments</comments>
		<pubDate>Tue, 02 Aug 2011 17:50:43 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[Medicinal Chemistry]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[New Products]]></category>
		<category><![CDATA[R & D]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1229</guid>
		<description><![CDATA[AstraZeneca today announced that AXANUM, a fixed dose combination of 81 mg low-dose ASA (acetylsalicylic acid) and 20 mg esomeprazole, has received positive agreement for approval in 23 European Union member countries and in Norway. AXANUM is indicated for prevention of cardiovascular (CV) events such as heart attack or stroke, in high-risk CV patients in [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/08/02/positive-agreement-received-for-approval-of-axanum-low-dose-asaesomeprazole-in-europe/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Daily pill can prevent HIV infection</title>
		<link>http://www.bioscreening.net/2011/07/14/daily-pill-can-prevent-hiv-infection/</link>
		<comments>http://www.bioscreening.net/2011/07/14/daily-pill-can-prevent-hiv-infection/#comments</comments>
		<pubDate>Thu, 14 Jul 2011 15:36:10 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Antibiotics]]></category>
		<category><![CDATA[Cell Analysis]]></category>
		<category><![CDATA[Discoveries, Innovations and Patents]]></category>
		<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[HIV Research]]></category>
		<category><![CDATA[Medicinal Chemistry]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[New Products]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[R & D]]></category>
		<category><![CDATA[Reports]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1211</guid>
		<description><![CDATA[The partners of people who have HIV can protect themselves from infection by taking a once-daily pill, two groundbreaking studies in Botswana, Kenya and Uganda have shown. The discovery could bring work to combat Aids close to a &#8220;tipping point&#8221;, experts say. Attempts to promote condom use to protect against HIV in the hardest-hit parts [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/07/14/daily-pill-can-prevent-hiv-infection/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Genentech to Appeal to F.D.A. for Breast Cancer Drug</title>
		<link>http://www.bioscreening.net/2011/06/27/genentech-to-appeal-to-f-d-a-for-breast-cancer-drug/</link>
		<comments>http://www.bioscreening.net/2011/06/27/genentech-to-appeal-to-f-d-a-for-breast-cancer-drug/#comments</comments>
		<pubDate>Mon, 27 Jun 2011 15:10:56 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Cancer Research]]></category>
		<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[FDA News]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[New Products]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[Oncology Research]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[R & D]]></category>
		<category><![CDATA[USA and Canada]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1182</guid>
		<description><![CDATA[Genentech this week will step up its efforts to keep the drug Avastin available as a treatment for breast cancer, urging the Food and Drug Administration to give it one more chance to prove the medicine works. At a hearing on Tuesday and Wednesday in suburban Washington, Genentech will ask the F.D.A. to reconsider its [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/06/27/genentech-to-appeal-to-f-d-a-for-breast-cancer-drug/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Experimental Type 1 diabetes vaccine fails during second step of trial</title>
		<link>http://www.bioscreening.net/2011/06/27/experimental-type-1-diabetes-vaccine-fails-during-second-step-of-trial/</link>
		<comments>http://www.bioscreening.net/2011/06/27/experimental-type-1-diabetes-vaccine-fails-during-second-step-of-trial/#comments</comments>
		<pubDate>Mon, 27 Jun 2011 15:07:18 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[Discoveries, Innovations and Patents]]></category>
		<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[New Products]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[R & D]]></category>
		<category><![CDATA[Reports]]></category>
		<category><![CDATA[USA and Canada]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1180</guid>
		<description><![CDATA[The quest for a vaccine to stop Type 1 diabetes in its tracks has hit a roadblock. An experimental drug failed in the second step of a three-phase trial on 145 American and Canadian patients who had just been diagnosed with the disease. The vaccine is based on an enzyme that is targeted by a [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/06/27/experimental-type-1-diabetes-vaccine-fails-during-second-step-of-trial/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Kidney improvement sustained by Abbott drug-study</title>
		<link>http://www.bioscreening.net/2011/06/24/kidney-improvement-sustained-by-abbott-drug-study/</link>
		<comments>http://www.bioscreening.net/2011/06/24/kidney-improvement-sustained-by-abbott-drug-study/#comments</comments>
		<pubDate>Fri, 24 Jun 2011 15:18:36 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[New Products]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[R & D]]></category>
		<category><![CDATA[Reports]]></category>
		<category><![CDATA[USA and Canada]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1177</guid>
		<description><![CDATA[NEW YORK, June 24 (Reuters) &#8211; Diabetics with moderate to severe chronic kidney disease showed significant and sustained improvement in kidney function through 52 weeks of treatment with a novel drug being developed by Abbott Laboratories (ABT.N), according to data from a midstage clinical trial. The oral drug, bardoxolone methyl, is the first medicine to [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/06/24/kidney-improvement-sustained-by-abbott-drug-study/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pfizer&#8217;s Remoxy Fails to Win FDA Approval</title>
		<link>http://www.bioscreening.net/2011/06/24/pfizers-remoxy-fails-to-win-fda-approval/</link>
		<comments>http://www.bioscreening.net/2011/06/24/pfizers-remoxy-fails-to-win-fda-approval/#comments</comments>
		<pubDate>Fri, 24 Jun 2011 15:13:22 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[FDA News]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[New Products]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[R & D]]></category>
		<category><![CDATA[USA and Canada]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1175</guid>
		<description><![CDATA[WASHINGTON &#8212; The latest attempt at an abuse-resistant formulation of oxycodone (Remoxy) failed to win approval from the FDA, according to a statement from Pfizer. Late Thursday, the company said it had received a complete response letter from the FDA, which described the reasons for the FDA&#8217;s decision. The FDA had turned down an earlier [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/06/24/pfizers-remoxy-fails-to-win-fda-approval/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New Drug Effectively Treats Hepatitis C</title>
		<link>http://www.bioscreening.net/2011/06/23/new-drug-effectively-treats-hepatitis-c/</link>
		<comments>http://www.bioscreening.net/2011/06/23/new-drug-effectively-treats-hepatitis-c/#comments</comments>
		<pubDate>Thu, 23 Jun 2011 20:36:04 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Discoveries, Innovations and Patents]]></category>
		<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[FDA News]]></category>
		<category><![CDATA[Hepatitis Research]]></category>
		<category><![CDATA[Medicinal Chemistry]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[New Products]]></category>
		<category><![CDATA[R & D]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1172</guid>
		<description><![CDATA[WEDNESDAY, June 22 (HealthDay News) &#8212; The recently approved drug Incivek, combined with two standard drugs, is highly effective at treating hepatitis C, a notoriously difficult-to-manage liver disease, two new studies show. The drug works not only in patients just starting treatment, but in those who failed earlier treatment, the research found. The hepatitis C [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/06/23/new-drug-effectively-treats-hepatitis-c/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>UPDATE 1-Pfizer stop-smoking pill raises heart risk-FDA</title>
		<link>http://www.bioscreening.net/2011/06/17/update-1-pfizer-stop-smoking-pill-raises-heart-risk-fda/</link>
		<comments>http://www.bioscreening.net/2011/06/17/update-1-pfizer-stop-smoking-pill-raises-heart-risk-fda/#comments</comments>
		<pubDate>Fri, 17 Jun 2011 15:13:48 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Cancer Research]]></category>
		<category><![CDATA[FDA News]]></category>
		<category><![CDATA[New Products]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[Oncology Research]]></category>
		<category><![CDATA[USA and Canada]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1163</guid>
		<description><![CDATA[WASHINGTON, June 16 (Reuters) &#8211; Pfizer Inc&#8217;s (PFE.N) stop-smoking drug Chantix can lead to a small increase in cardiovascular problems such as heart attacks for patients who already have cardiovascular disease, U.S. drug regulators said on Thursday. The Food and Drug Administration is changing the label for Chantix after reviewing the results of a clinical [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/06/17/update-1-pfizer-stop-smoking-pill-raises-heart-risk-fda/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDA Okays New HIV Drug</title>
		<link>http://www.bioscreening.net/2011/05/20/fda-okays-new-hiv-drug/</link>
		<comments>http://www.bioscreening.net/2011/05/20/fda-okays-new-hiv-drug/#comments</comments>
		<pubDate>Fri, 20 May 2011 17:56:02 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[FDA News]]></category>
		<category><![CDATA[HIV Research]]></category>
		<category><![CDATA[Medicinal Chemistry]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[New Products]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1108</guid>
		<description><![CDATA[WASHINGTON &#8212; The FDA has approved rilpivirine (Edurant) for the treatment of HIV patients who have not yet begun therapy. The drug, a non-nucleoside reverse transcriptase inhibitor, is intended to be used as part of highly active anti-retroviral therapy (HAART) with at least two other medications, the agency said. Rilpivirine, also known as TMC278, is [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/05/20/fda-okays-new-hiv-drug/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Microneedle Drug Delivery Systems Moving Toward Commercialization by Converging with Existing Delivery Technologies</title>
		<link>http://www.bioscreening.net/2011/05/04/microneedle-drug-delivery-systems-moving-toward-commercialization-by-converging-with-existing-delivery-technologies/</link>
		<comments>http://www.bioscreening.net/2011/05/04/microneedle-drug-delivery-systems-moving-toward-commercialization-by-converging-with-existing-delivery-technologies/#comments</comments>
		<pubDate>Wed, 04 May 2011 22:12:48 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Equipment & Supplies]]></category>
		<category><![CDATA[New Products]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1097</guid>
		<description><![CDATA[Evolutionary Design Enhancements Creating a Viable Path to the Market According to Greystone Research Associates (Amherst, NH) – For the past decade a small group of device development companies, often supported by academic partners and national government technology transfer programs, have been attempting to commercialize drug delivery products based on arrays of microneedles. By creating [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/05/04/microneedle-drug-delivery-systems-moving-toward-commercialization-by-converging-with-existing-delivery-technologies/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Accessing Nuclear Receptors with ActiTarg-N</title>
		<link>http://www.bioscreening.net/2011/04/25/accessing-nuclear-receptors-with-actitarg-n/</link>
		<comments>http://www.bioscreening.net/2011/04/25/accessing-nuclear-receptors-with-actitarg-n/#comments</comments>
		<pubDate>Mon, 25 Apr 2011 19:04:52 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Compound Libraries]]></category>
		<category><![CDATA[New Products]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[USA and Canada]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1094</guid>
		<description><![CDATA[TimTec adds new targeted library to its ActiTarg Series. ActiTarg-N gathers 1040 nuclear receptors ligands analogs. Nuclear receptors are inside-cell proteins that regulate gene transcription and affect wide range of biological functions throughout organism normal and pathological development. These are the super-family of 48 structurally related transcription factors that can be regulated by small molecules. [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/04/25/accessing-nuclear-receptors-with-actitarg-n/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>UPDATE 1-US panel says Optimer&#8217;s antibiotic effective</title>
		<link>http://www.bioscreening.net/2011/04/05/update-1-us-panel-says-optimers-antibiotic-effective/</link>
		<comments>http://www.bioscreening.net/2011/04/05/update-1-us-panel-says-optimers-antibiotic-effective/#comments</comments>
		<pubDate>Tue, 05 Apr 2011 18:51:34 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[FDA News]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[New Products]]></category>
		<category><![CDATA[USA and Canada]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1086</guid>
		<description><![CDATA[Optimer Pharmaceuticals Inc&#8217;s (OPTR.O) experimental antibiotic is safe and effective in treating a bacterial infection that causes diarrhea, a U.S. advisory panel said on Tuesday. The advisory panel of 13 independent experts voted unanimously that the drug was effective but said there were concerns regarding the drug&#8217;s use in pregnant women and children. However, the [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/04/05/update-1-us-panel-says-optimers-antibiotic-effective/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Higher bleeding risk seen in J&amp;J, Bayer clot drug</title>
		<link>http://www.bioscreening.net/2011/04/05/higher-bleeding-risk-seen-in-jj-bayer-clot-drug/</link>
		<comments>http://www.bioscreening.net/2011/04/05/higher-bleeding-risk-seen-in-jj-bayer-clot-drug/#comments</comments>
		<pubDate>Tue, 05 Apr 2011 18:44:59 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[FDA News]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[New Products]]></category>
		<category><![CDATA[Reports]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1084</guid>
		<description><![CDATA[A blood clot preventer from Johnson &#38; Johnson and Bayer caused a surprisingly high rate of bleeding in a trial of patients with acute illnesses, representing a significant setback for the drugmakers. Bayer AG shares fell 3.6 percent in Frankfurt on Tuesday. J&#38;J slid 0.6 percent on the New York Stock Exchange. Industry analysts had [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/04/05/higher-bleeding-risk-seen-in-jj-bayer-clot-drug/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>TimTec&#8217;s Contract Research Services</title>
		<link>http://www.bioscreening.net/2010/07/08/contract-research-services/</link>
		<comments>http://www.bioscreening.net/2010/07/08/contract-research-services/#comments</comments>
		<pubDate>Thu, 08 Jul 2010 19:22:09 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[ADMET Studies]]></category>
		<category><![CDATA[Drug-Like Compounds]]></category>
		<category><![CDATA[Medicinal Chemistry]]></category>
		<category><![CDATA[New Products]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[R & D]]></category>
		<category><![CDATA[Research Projects]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2010/07/08/contract-research-services/</guid>
		<description><![CDATA[High Quality Organic Synthesis and Medicinal Chemistry Contract Research Services at an Outstanding Value TimTec brings 15 years of expertise in organic chemistry design and supply for drug discovery closer to your supplemental bench-top requirements by launching The Organic Synthesis and Medicinal Chemistry Contract Research Services Division. TimTec scientists have a proven track record of [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/07/08/contract-research-services/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

